Author

Hiroki Komatsuda

Dana-Farber Cancer InstituteORCID 0000-0002-3783-2746Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Aaron N. HataiD· 1 shared Ann Marie EgloffiD· 1 shared Atrayee BhattacharyaiD· 1 shared Chendi LiiD· 1 shared Cong FuiD· 1 shared Donald W. KufeiD· 1 shared Hiroki OzawaiD· 1 shared Jiehui DengiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aaron N. HataORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors

Shinkichi Takamori, Naoki Haratake, Atrayee Bhattacharya, Hiroki Ozawa, Keisuke Shigeta, Mai Onishi, Kentaro Nonaka, Takefumi Komiya, Hiroki Komatsuda, Tomoyoshi Takenaka, Tomoharu Yoshizumi, Chendi Li, Jiehui Deng, Aaron N. Hata, Kwok‐Kin Wong, , Donald W. Kufe

This study identifies M1C as a driver of sotorasib resistance in NSCLC KRAS G12C mutant tumors and shows that targeting M1C improves treatment outcomes.

Oncogene · Aug 5, 2026Peer-reviewedCancer Biology

Cancer vaccine attenuates carcinogen induced head and neck cancer with impaired early T cell response

Michihisa Kono, Masahiro Rokugo, John D. Quadarella, Shin Saito, Hiroki Komatsuda, Cong Fu, Sook-Bin Woo, Ann Marie Egloff, Ravindra Uppaluri

This study shows that a cancer vaccine combined with anti-PD-1 therapy reduces tumor burden and improves survival in a head and neck cancer model with impaired T cell responses.

bioRxiv · Jun 26, 2024 · PreprintCancer Biology